Astellas Pharma hires Head of Global Pharmacovigilance

Songlin Hue will be located in Northbrook, Illinois

Japanese pharmaceutical firm Astellas Pharma has named Songlin Hue as Head of Global Pharmacovigilance. He will be located at Astellas’ headquarters for the Americas in Northbrook, Illinois, US and report to Sef Kurstjens, who recently became Chief Medical Officer at the company.

Astellas has now hired global heads in the areas of Pharmacovigilance, Medical Affairs, Regulatory Affairs, Clinical and Research Quality Assurance, and Quality Assurance.

In more than 20 years in the pharmaceutical industry, Xue has held increasingly senior roles with global responsibilities in drug safety and pharmacoepidemiology. Most recently, he was Senior Vice President, Head of Global Pharmacovigilance at Takeda Pharmaceuticals.

Prior to joining Takeda, Xue held posts at global pharmaceutical companies such as Novartis and Wyeth.

You may also like

Regulatory

Astellas' Vyloytm plus chemo gains FDA approval for gastric adenocarcinoma

The drug is the first CLDN18.2 targeted therapy to be approved in the US, and can further extend a patient's PFS and OS compared with chemotherapy alone
Regulatory

Padcev plus Keytruda approved for advanced urothelial cancer by the EC

The therapeutic combination will now be named as the first-line, standard of care treatment for metastatic or advanced bladder cancer
Regulatory

Ubiquigent enters agreement with Astellas subsidiary, Nanna Therapeutics

Agreement leverages Ubiquigent’s DUB-focused drug discovery platform to support the development of novel therapeutic candidates for multiple disease targets selected by Nanna Therapeutics
Regulatory

Antifungal agent – isavuconazole

A new antifungal agent has been granted fast-track status by the FDA, as well as being designated a qualified infectious disease product, and an orphan drug for invasive aspergillosis and mucormycosis
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

NCEs target cancer

As the number of NCE approvals continues to rise, researchers are looking increasingly at anticancer treatments, particularly those involving new tyrosine kinase inhibitors. Dr Sarah Houlton sums up the latest arrivals on the scene
Regulatory

Overactive bladder – mirabegron

Current drug treatments for overactive bladder rely on antimuscarinic drugs but these do not always work, and commonly cause dry mouth symptoms and an increase in intraocular pressure
Regulatory

Anticancer agent – MDV-3100

Prostate cancer treatment typically involves some way of blocking the activation of androgen receptors in the prostate, but if this does not work the next mode of attack involves antiandrogen drugs
Subscribe now